ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer

John J. Arcaroli, Rebecca W. Powell, Marileila Varella-Garcia, Martine McManus, Aik-Choon Tan, Kevin S. Quackenbush, Todd M. Pitts, Dexiang Gao, Anna Spreafico, Arvind Dasari, Basel M. Touban, Wells A. Messersmith

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The Notch signaling pathway has been shown to be upregulated in colorectal cancer (CRC) and important for the self-renewal of cancer stem cells. In this study, we evaluated the efficacy of PF-03084014, a γ-secretase inhibitor, in combination with irinotecan to identify the effects of treatment on tumor recurrence and the tumor-initiating population in our CRC preclinical explant model. The combination of PF-03084014 and irinotecan had the greatest effect at reducing tumor growth on four CRC tumors when compared with treatment with PF-03084014 or irinotecan alone. The combination significantly reduced tumor recurrence in two CRC explants (CRC001 and CRC036) after treatment was discontinued. Both of these tumors exhibited elevated baseline levels of Notch pathway activation as well as an increase in NOTCH1 gene copy number when compared with the two CRC explants (CRC026 and CRC027) where tumors reappeared quickly after termination of treatment. Isolation and injection of aldehyde dehydrogenase (ALDH+ and ALDH-) cells in an in vivo explant model demonstrated that the ALDH+ cell population were tumorigenic. Evaluation of the ALDH+ cells after 28 days of treatment showed that the combination reduced the ALDH+ population in the tumors that did not regrow. Furthermore, ALDH+ cells from CRC001 and CRC027 were injected in vivo and treated immediately for 28 days. Two months after treatment, tumors were evident in the combination treatment group for CRC027 but not for CRC036. These results indicate the combination of PF-03084014 and irinotecan may be effective in reducing tumor recurrence in CRC patients whose tumors exhibit elevated levels of the Notch pathway.

Original languageEnglish
Pages (from-to)370-381
Number of pages12
JournalMolecular Oncology
Volume6
Issue number3
DOIs
Publication statusPublished - 2012 Jun 1
Externally publishedYes

Fingerprint

irinotecan
Amyloid Precursor Protein Secretases
Gene Dosage
Neoplastic Stem Cells
Colorectal Neoplasms
Neoplasms
Recurrence
Therapeutics
Population
Aldehyde Dehydrogenase

Keywords

  • Cancer stem cell
  • Colorectal cancer
  • Gamma-secretase inhibitor
  • Notch

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine

Cite this

ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer. / Arcaroli, John J.; Powell, Rebecca W.; Varella-Garcia, Marileila; McManus, Martine; Tan, Aik-Choon; Quackenbush, Kevin S.; Pitts, Todd M.; Gao, Dexiang; Spreafico, Anna; Dasari, Arvind; Touban, Basel M.; Messersmith, Wells A.

In: Molecular Oncology, Vol. 6, No. 3, 01.06.2012, p. 370-381.

Research output: Contribution to journalArticle

Arcaroli, JJ, Powell, RW, Varella-Garcia, M, McManus, M, Tan, A-C, Quackenbush, KS, Pitts, TM, Gao, D, Spreafico, A, Dasari, A, Touban, BM & Messersmith, WA 2012, 'ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer', Molecular Oncology, vol. 6, no. 3, pp. 370-381. https://doi.org/10.1016/j.molonc.2012.03.004
Arcaroli, John J. ; Powell, Rebecca W. ; Varella-Garcia, Marileila ; McManus, Martine ; Tan, Aik-Choon ; Quackenbush, Kevin S. ; Pitts, Todd M. ; Gao, Dexiang ; Spreafico, Anna ; Dasari, Arvind ; Touban, Basel M. ; Messersmith, Wells A. / ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer. In: Molecular Oncology. 2012 ; Vol. 6, No. 3. pp. 370-381.
@article{9ffb3d88d2f644b2966356d43246e2e6,
title = "ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer",
abstract = "The Notch signaling pathway has been shown to be upregulated in colorectal cancer (CRC) and important for the self-renewal of cancer stem cells. In this study, we evaluated the efficacy of PF-03084014, a γ-secretase inhibitor, in combination with irinotecan to identify the effects of treatment on tumor recurrence and the tumor-initiating population in our CRC preclinical explant model. The combination of PF-03084014 and irinotecan had the greatest effect at reducing tumor growth on four CRC tumors when compared with treatment with PF-03084014 or irinotecan alone. The combination significantly reduced tumor recurrence in two CRC explants (CRC001 and CRC036) after treatment was discontinued. Both of these tumors exhibited elevated baseline levels of Notch pathway activation as well as an increase in NOTCH1 gene copy number when compared with the two CRC explants (CRC026 and CRC027) where tumors reappeared quickly after termination of treatment. Isolation and injection of aldehyde dehydrogenase (ALDH+ and ALDH-) cells in an in vivo explant model demonstrated that the ALDH+ cell population were tumorigenic. Evaluation of the ALDH+ cells after 28 days of treatment showed that the combination reduced the ALDH+ population in the tumors that did not regrow. Furthermore, ALDH+ cells from CRC001 and CRC027 were injected in vivo and treated immediately for 28 days. Two months after treatment, tumors were evident in the combination treatment group for CRC027 but not for CRC036. These results indicate the combination of PF-03084014 and irinotecan may be effective in reducing tumor recurrence in CRC patients whose tumors exhibit elevated levels of the Notch pathway.",
keywords = "Cancer stem cell, Colorectal cancer, Gamma-secretase inhibitor, Notch",
author = "Arcaroli, {John J.} and Powell, {Rebecca W.} and Marileila Varella-Garcia and Martine McManus and Aik-Choon Tan and Quackenbush, {Kevin S.} and Pitts, {Todd M.} and Dexiang Gao and Anna Spreafico and Arvind Dasari and Touban, {Basel M.} and Messersmith, {Wells A.}",
year = "2012",
month = "6",
day = "1",
doi = "10.1016/j.molonc.2012.03.004",
language = "English",
volume = "6",
pages = "370--381",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer

AU - Arcaroli, John J.

AU - Powell, Rebecca W.

AU - Varella-Garcia, Marileila

AU - McManus, Martine

AU - Tan, Aik-Choon

AU - Quackenbush, Kevin S.

AU - Pitts, Todd M.

AU - Gao, Dexiang

AU - Spreafico, Anna

AU - Dasari, Arvind

AU - Touban, Basel M.

AU - Messersmith, Wells A.

PY - 2012/6/1

Y1 - 2012/6/1

N2 - The Notch signaling pathway has been shown to be upregulated in colorectal cancer (CRC) and important for the self-renewal of cancer stem cells. In this study, we evaluated the efficacy of PF-03084014, a γ-secretase inhibitor, in combination with irinotecan to identify the effects of treatment on tumor recurrence and the tumor-initiating population in our CRC preclinical explant model. The combination of PF-03084014 and irinotecan had the greatest effect at reducing tumor growth on four CRC tumors when compared with treatment with PF-03084014 or irinotecan alone. The combination significantly reduced tumor recurrence in two CRC explants (CRC001 and CRC036) after treatment was discontinued. Both of these tumors exhibited elevated baseline levels of Notch pathway activation as well as an increase in NOTCH1 gene copy number when compared with the two CRC explants (CRC026 and CRC027) where tumors reappeared quickly after termination of treatment. Isolation and injection of aldehyde dehydrogenase (ALDH+ and ALDH-) cells in an in vivo explant model demonstrated that the ALDH+ cell population were tumorigenic. Evaluation of the ALDH+ cells after 28 days of treatment showed that the combination reduced the ALDH+ population in the tumors that did not regrow. Furthermore, ALDH+ cells from CRC001 and CRC027 were injected in vivo and treated immediately for 28 days. Two months after treatment, tumors were evident in the combination treatment group for CRC027 but not for CRC036. These results indicate the combination of PF-03084014 and irinotecan may be effective in reducing tumor recurrence in CRC patients whose tumors exhibit elevated levels of the Notch pathway.

AB - The Notch signaling pathway has been shown to be upregulated in colorectal cancer (CRC) and important for the self-renewal of cancer stem cells. In this study, we evaluated the efficacy of PF-03084014, a γ-secretase inhibitor, in combination with irinotecan to identify the effects of treatment on tumor recurrence and the tumor-initiating population in our CRC preclinical explant model. The combination of PF-03084014 and irinotecan had the greatest effect at reducing tumor growth on four CRC tumors when compared with treatment with PF-03084014 or irinotecan alone. The combination significantly reduced tumor recurrence in two CRC explants (CRC001 and CRC036) after treatment was discontinued. Both of these tumors exhibited elevated baseline levels of Notch pathway activation as well as an increase in NOTCH1 gene copy number when compared with the two CRC explants (CRC026 and CRC027) where tumors reappeared quickly after termination of treatment. Isolation and injection of aldehyde dehydrogenase (ALDH+ and ALDH-) cells in an in vivo explant model demonstrated that the ALDH+ cell population were tumorigenic. Evaluation of the ALDH+ cells after 28 days of treatment showed that the combination reduced the ALDH+ population in the tumors that did not regrow. Furthermore, ALDH+ cells from CRC001 and CRC027 were injected in vivo and treated immediately for 28 days. Two months after treatment, tumors were evident in the combination treatment group for CRC027 but not for CRC036. These results indicate the combination of PF-03084014 and irinotecan may be effective in reducing tumor recurrence in CRC patients whose tumors exhibit elevated levels of the Notch pathway.

KW - Cancer stem cell

KW - Colorectal cancer

KW - Gamma-secretase inhibitor

KW - Notch

UR - http://www.scopus.com/inward/record.url?scp=84861461140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861461140&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2012.03.004

DO - 10.1016/j.molonc.2012.03.004

M3 - Article

C2 - 22521243

AN - SCOPUS:84861461140

VL - 6

SP - 370

EP - 381

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 3

ER -